Navigation Links
RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute
Date:1/31/2013

NORCROSS, Ga., Jan. 31, 2013 /PRNewswire/ -- RayBiotech, Inc. announced today that it has executed a master services agreement with Banner Sun Health Research Institute (BSHRI) of Sun City, Arizona.  Under the terms of the agreement, RayBiotech will provide priority services for the biochemical analysis of disease markers in biological samples.  A particular focus of the pact will be on the characterization of key biomarkers for the study of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases.  Financial terms were not disclosed.

RayBiotech's President, Chief Operating Officer and Co-Founder, Rani Huang stated, "We are excited about providing biomarker analysis services to BSHRI researchers.  Banner Sun Health Research Institute is a unique world-class research organization that has outstanding tissue depository program, clinical center that conducts a large number of clinical trials, and research scientists who are dedicated to translational research in neurodegenerative and cardiovascular disorders.  We believe that the collaboration will yield promising new opportunities facilitating early diagnosis of these devastating diseases."

BSHRI research scientists are involved in biomarker discovery research in both Alzheimer's and Parkinson's diseases.  Senior Scientist Dr. LihFen Lue said, "As we continue to strive towards a better understanding of the molecular mechanisms at early stage of these neurodegenerative diseases, we also recognize the importance of identifying proteins present in the biofluid that could be used as potential disease biomarkers. Fortunately, we have more cutting-edge tools these days to do this crucial research.  Raybiotech Quantibody® array is one of these very useful tools."

RayBiotech provides a valuable biochemical platform to assess both the identity and quantity of these markers in a comprehensive high-throughput format.  The master service agreement with BSHRI is an important step demonstrating the dedication to provide outstanding products and service from RayBiotech to the scientific community.

About RayBiotech, Inc.

In 2001 RayBiotech (http://www.raybiotech.com) introduced the first commercially available cytokine antibody array. With a focus on translating scientific knowledge into improved health, RayBiotech continues to pioneer advances in high-throughput platforms for identifying disease mechanisms, screening and validation of biomarkers and identification of drug targets.  RayBiotech products are featured in thousands of publications, including: Nature, Nature Medicine, Cell, Lancet, PNAS and many others. Offering the largest selection of protein arrays, RayBiotech has established a reputation for high quality and innovation in the research community. A spin-off from Emory University, RayBiotech is privately owned, with headquarters in metropolitan Atlanta.

About Banner Sun Health Research Institute

Founded in 1986 as a private, nonprofit biomedical research center, Banner Sun Health Research Institute (BSHRI) conduct basic and translational research, clinical research, prevention and education programs specialized in the study of normal aging and certain age-related diseases, including Alzheimer's, Parkinson's  and Parkinson's diseases, and cardiovascular disease.  The Institute is the applicant organization for the Arizona Alzheimer's Disease Center, a leading statewide research program that has been recognized and supported by the National Institutes of Health (NIH). Research at the BSHRI is funded by grants from the NIH, the Michael Fox Foundation, the Alzheimer's Association, and private donations.  The Institute maintains collaborations with many nationally- and internationally-recognized institutions and provides highest quality of autopsy tissues to research community through a very successful Whole Body and Brain Tissue Depository Program.  The clinical center at the BSHRI also participates in many important clinical trials and biomarker discovery research.  

For More Information:

Rob Burgess , PhD
Director, Business Development
RayBiotech, Inc.
Phone: 770-729-2992
Email: rob@raybiotech.com


'/>"/>
SOURCE RayBiotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Stanford and MIT scientists win Perl-UNC Neuroscience prize
2. 6th Annual Canadian Neuroscience Meeting, Vancouver, May 20-23, 2012
3. UCSF pair win Gruber Foundation Neuroscience prize
4. Wiring bats for neuroscience research
5. Media registration opens for Neuroscience 2012, worlds largest brain science meeting
6. Neuroscience: The extraordinary ease of ordinal series
7. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
8. Trial seeks improved lung-cancer screening by combining imaging and biomarkers
9. Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease
10. VTT and GE Healthcare developing novel biomarkers to predict Alzheimers disease
11. New biomarker for common lung cancer predicts responses to chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Ky. , June 23, 2016 ... two Phase 1 clinical trials of its complement ... placebo-controlled, single and multiple ascending dose studies designed ... pharmacodynamics (PD) of subcutaneous injection in healthy adult ... subcutaneously (SC) either as a single dose (ranging ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... new line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC ... in Chicago. The result of a collaboration among several companies with expertise in ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
Breaking Biology Technology: